KVISTGAARD, Denmark, May 31, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)
announces that pursuant to section 6 of Executive Order no. 1442 of December
13, 2013 on Issuers' Disclosure Obligations, the total nominal value of Bavarian
Nordic A/S' share capital is DKK 261,128,630 at the end of May 2014, which is
made up of 26,112,863 shares of a nominal value of DKK 10 each, corresponding to
26,112,863 votes.

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEX®. Bavarian Nordic's shares are
listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO,
Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in
the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone
+45 61 77 47 43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654